IL6 and neoplasm: In non-small cell lung cancer (NSCLC), FXR acts as a tumor-promoting driver, transactivating IL-6 and IL-6ST and activating the Jak2/signal transducer and activator of transcription 3 (STAT3) pathway, thereby enhancing metastatic potential and poor prognosis [133].